Entries by

La Jolla Pharmaceutical Company Announces First Quarter 2015 Financial Results and Corporate Highlights

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported first quarter 2015 financial results and highlighted recent corporate progress and near-term milestones. Recent Corporate Highlights La Jolla reached agreement […]

La Jolla Pharmaceutical Company Appoints Lakhmir S. Chawla, M.D., as Chief Medical Officer

La Jolla Pharmaceutical Company Appoints Lakhmir S. Chawla, M.D., as Chief Medical Officer SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Lakhmir S. Chawla, M.D., will be […]

La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension

La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated […]

La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its Phase 2b clinical trial of GCS-100 for the treatment of advanced chronic kidney disease (CKD) […]

La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assesment (SPA) for […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference

SAN DIEGO, CA – February 4, 2015 – La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate […]

La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement

Dec. 9, 2014 21:01 UTC License Covers Intellectual Property Relating to LJPC-501 SAN DIEGO & WASHINGTON–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and the George Washington University (GW), today announced that La […]

Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney Week

Primary Endpoint Met; Statistically Significant Improvement in Kidney Function Observed Improvement More Pronounced in Diabetic Patients Results Reproduced in Extension Study   PHILADELPHIA, PA – November 12, 2014 – La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients […]

La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights

SAN DIEGO, CA – November 12, 2014 – La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress and near-term milestones. […]

La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week

Oct. 23, 2014 20:01 UTC La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“the Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced […]